{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "asset_id": "zidesamtinib",
    "internal_id": "NVL-520",
    "data_source": "Nuvalent Overview January 12, 2026; Drilon et al WCLC 2025",
    "extraction_date": "2026-02-04",
    "last_updated": "2026-02-04"
  },
  "asset": {
    "name": "zidesamtinib",
    "internal_id": "NVL-520",
    "modality": "Small molecule tyrosine kinase inhibitor",
    "route": "Oral, once daily",
    "dose": "100 mg QD (RP2D)",
    "formulation": "Oral pill"
  },
  "target": {
    "primary_target": "ROS1",
    "target_class": "Receptor tyrosine kinase",
    "biology": {
      "function": "ROS1 is a receptor tyrosine kinase that when fused to various partner genes (e.g., CD74-ROS1, SLC34A2-ROS1) creates oncogenic fusion proteins that drive tumor growth through constitutive kinase activation",
      "prevalence": "~1-3% of NSCLC; majority diagnosed at advanced/metastatic stage",
      "patient_demographics": "Often younger, never-smokers",
      "cns_involvement": {
        "at_diagnosis": "20-40% present with brain metastases",
        "at_1L_progression": "30-55% have brain metastases"
      },
      "resistance_mechanisms": {
        "primary_mutation": "G2032R (observed in ~40% progressing on crizotinib)",
        "other_mutations": ["G1957A", "L1982V", "S1986F", "F2004C", "F2004V", "G2032K", "D2033N", "L2026M"]
      }
    },
    "genetic_validation": {
      "oncogenic_driver": "Yes - ROS1 fusions are validated oncogenic drivers in NSCLC",
      "predictive_biomarker": "ROS1 fusion status by FISH, IHC, or NGS",
      "therapeutic_precedent": "Multiple approved ROS1 TKIs (crizotinib, entrectinib, repotrectinib, taletrectinib)"
    },
    "why_good_target": {
      "rationale": [
        "Validated oncogenic driver with proven therapeutic tractability",
        "Current therapies have significant limitations (resistance, CNS activity, TRK-related toxicity)",
        "Younger patient population with long life expectancy if disease controlled",
        "Potential for chronic disease management with improved therapies"
      ],
      "unmet_need": [
        "No approved therapy active after dual TRK/ROS1 inhibitors (repotrectinib, taletrectinib)",
        "Treatment-limiting CNS adverse events with current TRK/ROS1 inhibitors",
        "Limited durability - crizotinib mPFS only 19.3 months vs lorlatinib mPFS not reached in ALK"
      ]
    }
  },
  "mechanism": {
    "mechanism_of_action": "ROS1-selective, TRK-sparing tyrosine kinase inhibitor",
    "binding_mode": "ATP-competitive kinase inhibitor designed to fit the ROS1 kinase domain while avoiding the TRK kinase binding pocket",
    "selectivity_profile": {
      "ros1_vs_trkb": "670x selectivity for ROS1 over TRKB",
      "ros1_g2032r_vs_trkb": "240x selectivity for ROS1 G2032R over TRKB",
      "comparison_to_competitors": {
        "crizotinib": "7.7x selectivity for ROS1 vs TRKB",
        "entrectinib": "3.4x selectivity for ROS1 vs TRKB",
        "repotrectinib": "5.8x selectivity for ROS1 vs TRKB",
        "taletrectinib": "1.4x selectivity for ROS1 vs TRKB"
      }
    },
    "in_vitro_activity": {
      "wild_type_ros1": "Sub-10nM IC50",
      "ros1_mutants": {
        "G2032R": "Sub-10nM IC50",
        "S1986F": "Sub-10nM IC50",
        "F2004C": "Sub-10nM IC50",
        "F2004V": "Sub-10nM IC50",
        "L2026M": "Sub-10nM IC50",
        "D2033N": "Sub-10nM IC50"
      },
      "assay_type": "3-day cell viability assays in Ba/F3 expressing WT or mutant CD74-ROS1 fusion"
    },
    "brain_penetration": {
      "kp_uu": "~0.1 (unbound brain:plasma ratio)",
      "comparison": "Similar to preclinical observations for lorlatinib",
      "preclinical_intracranial_efficacy": "Durable inhibition of intracranially implanted Ba/F3 CD74-ROS1 G2032R luciferase cells at 3 mg/kg BID; superior to repotrectinib 75 mg/kg BID and taletrectinib 100 mg/kg QD"
    }
  },
  "clinical_data": {
    "trial_name": "ARROS-1",
    "clinicaltrials_gov": "NCT05118789",
    "trial_design": {
      "phase": "Phase 1/2",
      "design": "Global first-in-human, open-label, multi-cohort",
      "phase_1_initiation": "January 2022",
      "phase_2_initiation": "September 2023 (RP2D: 100 mg QD)",
      "registration_intent": "Yes, for TKI pre-treated and TKI-naïve ROS1+ NSCLC"
    },
    "enrollment": {
      "phase_1_phase_2_total": {
        "as_of_june_16_2025": 539,
        "phase_1": 104,
        "phase_2": 435
      },
      "enrollment_momentum": "Strong enrollment demonstrates enthusiasm and clear medical need"
    },
    "data_cutoff": "March 21, 2025",
    "populations": {
      "pivotal_safety": {
        "n": 432,
        "description": "ROS1+ NSCLC treated at RP2D as of March 21, 2025",
        "median_duration_exposure": "5 months (range 0-32)"
      },
      "tki_pretreated_efficacy": {
        "n": 117,
        "description": "Treated at RP2D by May 31, 2024 to allow ≥6 months DOR follow-up"
      },
      "tki_naive_preliminary": {
        "n": 35,
        "description": "Treated by August 31, 2024"
      }
    },
    "tki_pretreated_results": {
      "population_characteristics": {
        "n": 117,
        "median_age": "57 (range 31-83)",
        "female": "66 (56%)",
        "never_smoker": "80 (68%)",
        "geographic_region": {
          "asia_pacific": "30 (26%)",
          "europe": "38 (32%)",
          "north_america": "49 (42%)"
        },
        "ecog_ps": {
          "0": "45 (38%)",
          "1": "72 (62%)"
        },
        "active_cns_disease": "57 (49%)",
        "ros1_g2032r_mutation": "26 (22%)",
        "any_secondary_ros1_mutation": "42 (36%)",
        "median_prior_lines": "2 (range 1-11)",
        "prior_chemotherapy": "62 (53%)",
        "prior_tkis": {
          "1_prior_crizotinib_or_entrectinib": "55 (47%)",
          "1_prior_repotrectinib_or_taletrectinib": "4 (3%)",
          "2_or_more_prior": "58 (50%)"
        }
      },
      "efficacy": {
        "any_prior_tki": {
          "n": 117,
          "orr": "44% (51/117)",
          "orr_95ci": "[34, 53]",
          "cr": "1% (1/117)",
          "dor_6_months": "84% [95% CI: 71, 92]",
          "dor_12_months": "78% [95% CI: 62, 88]",
          "dor_18_months": "62% [95% CI: 28, 84]",
          "median_dor": "22 months [95% CI: 17, NE] - emerging, continues to mature",
          "median_pfs": "9.7 months [95% CI: 5.5, NE]",
          "median_followup": "11.1 months (range 0.2-25.6)"
        },
        "1_prior_tki_crizotinib_or_entrectinib": {
          "n": 55,
          "orr": "51% (28/55) [95% CI: 37, 65]",
          "cr": "2% (1/55)",
          "dor_6_months": "93% [95% CI: 74, 98]",
          "dor_12_months": "93% [95% CI: 74, 98]",
          "dor_18_months": "93% [95% CI: 74, 98]",
          "median_dor": "22 months [95% CI: 22, NE] - continues to mature",
          "median_pfs": "23.8 months [95% CI: 23.8, NE]",
          "median_followup": "11.8 months (range 1.2-25.6)",
          "subgroup_prior_crizotinib_only": {
            "n": 28,
            "orr": "68% (19/28)",
            "progression_events_among_responders": 0,
            "dor_range": "7.3+ to 23.2+ months",
            "pfs_6_12_18_months": "89% [95% CI: 70, 96]"
          },
          "subgroup_prior_entrectinib_only": {
            "n": 27,
            "orr": "33% (9/27)"
          }
        },
        "2_or_more_prior_tkis": {
          "n": 58,
          "orr": "38% (22/58) [95% CI: 26, 52]",
          "dor_6_months": "71% [95% CI: 46, 86]",
          "dor_12_months": "56% [95% CI: 29, 76]"
        },
        "prior_repotrectinib": {
          "n": 17,
          "orr": "47% (8/17)",
          "dor_range": "3.5 to 17.2 months"
        },
        "prior_taletrectinib": {
          "n": 7,
          "orr": "43% (3/7)",
          "dor_range": "5.2 to 7.0+ months"
        },
        "ros1_g2032r_mutation": {
          "any_prior_tki": {
            "n": 26,
            "orr": "54% (14/26)",
            "dor_6_months": "79% [95% CI: 47, 93]",
            "dor_12_months": "60% [95% CI: 28, 81]",
            "median_dor": "17.2 months [95% CI: 3.7, NE] - emerging, continues to mature"
          },
          "prior_crizotinib_or_entrectinib_only": {
            "n": 6,
            "orr": "83% (5/6)",
            "dor_6_months": "80% [95% CI: 20, 97]",
            "dor_12_months": "80% [95% CI: 20, 97]",
            "progression_events_among_responders": 1
          }
        }
      },
      "intracranial_activity": {
        "measurable_cns_lesions_any_prior_tki": {
          "n": 56,
          "ic_orr": "48% (27/56, includes 2 unconfirmed)",
          "ic_cr": "20% (11/56)",
          "ic_dor_6_months": "79% [95% CI: 56, 91]",
          "ic_dor_12_months": "71% [95% CI: 46, 87]"
        },
        "measurable_cns_lesions_prior_crizotinib_only": {
          "n": 13,
          "ic_orr": "85% (11/13)",
          "ic_cr": "54% (7/13)",
          "ic_dor_6_months": "91% [95% CI: 51, 99]",
          "ic_dor_12_months": "91% [95% CI: 51, 99]",
          "cns_progression_events_among_responders": 1
        },
        "prior_brain_penetrant_tki": {
          "n": 43,
          "ic_orr": "37% (16/43, includes 4 IC-CRs) [95% CI: 23, 53]"
        },
        "no_baseline_brain_mets": "No CNS progression observed among patients who entered without brain metastases at baseline per BICR"
      }
    },
    "tki_naive_results": {
      "population": {
        "n": 35,
        "description": "Response-evaluable TKI-naïve patients"
      },
      "efficacy": {
        "orr": "89% (31/35)",
        "cr": "9% (3/35, includes 1 unconfirmed CR following confirmed PR)",
        "dor_6_months": "96% [95% CI: 76, 99]",
        "dor_12_months": "96% [95% CI: 76, 99]",
        "dor_range": "1.9+ to 13.9+ months",
        "progression_events_among_responders": 2
      },
      "intracranial_activity": {
        "n": 6,
        "ic_orr": "83% (5/6)",
        "ic_cr": "67% (4/6)",
        "cns_progression_events": 0,
        "ic_dor_range": "4.6+ to 11.1+ months"
      },
      "note": "Enrollment and follow-up ongoing in registration-directed TKI-naïve cohort of ARROS-1"
    },
    "safety": {
      "population": 432,
      "dose_reduction_due_to_teae": "10% (43/432)",
      "most_common_dose_reduction_reasons": ["Peripheral edema (n=8)", "Blood CPK increased (n=4)", "Peripheral sensory neuropathy (n=4)", "Arthralgia (n=3)", "Paresthesia (n=3)"],
      "discontinuation_due_to_teae": "2% (10/432)",
      "most_common_discontinuation_reasons": ["Pneumonia (n=3)"],
      "teaes_15_percent_or_more": [
        {"term": "Peripheral edema", "any_grade": "36%", "grade_3_plus": "0.7%"},
        {"term": "Constipation", "any_grade": "17%", "grade_3_plus": "0"},
        {"term": "Blood CPK increased", "any_grade": "16%", "grade_3_plus": "3.5%"},
        {"term": "Fatigue", "any_grade": "16%", "grade_3_plus": "0.7%"},
        {"term": "Dyspnea", "any_grade": "15%", "grade_3_plus": "3.0%"}
      ],
      "treatment_related_ae_15_percent_or_more": [
        {"term": "Peripheral edema", "any_grade": "29%"}
      ],
      "key_safety_message": "Generally safe, well-tolerated, consistent with ROS1-selective, TRK-sparing design"
    }
  },
  "investment_analysis": {
    "stage_value": "Late-stage with NDA accepted; highest near-term probability of approval",
    "differentiation_strength": "Strong - only ROS1-selective, TRK-sparing inhibitor",
    "competitive_position": "Potentially best-in-class for durability + tolerability across lines",
    "data_quality": "High - pivotal data from global Phase 1/2 with BICR",
    "regulatory_pathway": "Standard NDA accepted; PDUFA September 18, 2026",
    "commercial_potential": {
      "addressable_market": "~1-3% of NSCLC; US peak sales opportunity $570M-855M",
      "pricing_assumptions": "~$32,000/month (2026 pricing based on repotrectinib)",
      "key_commercial_factors": [
        "First ROS1-selective option differentiates vs TRK/ROS1 inhibitors",
        "Tolerability advantage enables long-term therapy",
        "Durability data supports building prevalent treated population"
      ]
    },
    "key_data_to_watch": [
      "PDUFA outcome (September 18, 2026)",
      "TKI-naïve label expansion data and submission (2H 2026)",
      "Long-term durability follow-up",
      "Real-world commercial uptake post-launch"
    ]
  },
  "catalysts": [
    {
      "event": "PDUFA target action date",
      "timing": "September 18, 2026",
      "significance": "First US approval decision"
    },
    {
      "event": "US commercial launch in TKI pre-treated ROS1+ NSCLC",
      "timing": "2H 2026",
      "significance": "First revenue generation",
      "dependency": "Pending FDA approval"
    },
    {
      "event": "TKI-naïve ROS1+ NSCLC data submission to FDA",
      "timing": "2H 2026",
      "significance": "Potential for line-agnostic label"
    },
    {
      "event": "Ongoing enrollment in ROS1+ solid tumors (adult and pediatric)",
      "timing": "Ongoing",
      "significance": "Potential indication expansion"
    }
  ]
}
